Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag long-term safety in pulmonary arterial hypertension (China extension of GRIPHON OL)
CTR20132227Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Dec 2016; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20132227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132227.